Erste Group Bank Brokers Boost Earnings Estimates for AbbVie

Key Points

• Erste Group Bank raised its FY2026 EPS estimate for AbbVie to $14.26 from $14.13 and also projected FY2027 EPS of $16.18. The new estimate remains close to the broader consensus of $14.32 per share.
• Other analysts have been mostly constructive on AbbVie, with recent rating changes including Bank of America and DZ Bank upgrading the stock. MarketBeat data shows an overall Moderate Buy rating and an average price target of $252.90.
• AbbVie recently posted better-than-expected Q1 results, with EPS of $2.65 and revenue of $15 billion, and the stock was down only slightly around $201.24. The company also continues to offer a 3.4% dividend yield.

AbbVie Inc. (NYSE:ABBV - Free Report) - Erste Group Bank upped their FY2026 earnings per share (EPS) estimates for AbbVie in a research report issued on Tuesday, May 5th. Erste Group Bank analyst H. Engel now expects that the company will earn $14.26 per share for the year, up from their previous forecast of $14.13. The consensus estimate for AbbVie's current full-year earnings is $14.32 per share. Erste Group Bank also issued estimates for AbbVie's FY2027 earnings at $16.18 EPS.

Several other research analysts have also weighed in on the company. Bank of America raised AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price target on the stock in a research report on Thursday, April 30th. Citigroup dropped their price target on AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 27th. UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 4th. Finally, DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $252.90.

AbbVie Stock Down 0.2%

Shares of NYSE ABBV opened at $201.24 on Monday. AbbVie has a 12 month low of $176.57 and a 12 month high of $244.81. The company has a market cap of $355.83 billion, a price-to-earnings ratio of 99.13, a P/E/G ratio of 0.70 and a beta of 0.32. The business has a fifty day simple moving average of $213.18 and a 200-day simple moving average of $221.00.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the business posted $2.46 earnings per share. AbbVie's revenue was up 12.4% compared to the same quarter last year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 340.89%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company's stock.

Institutional Trading of AbbVie

Several hedge funds have recently added to or reduced their stakes in the business. Oslo Pensjonsforsikring AS bought a new stake in AbbVie during the 1st quarter valued at approximately $1,330,000. HORAN Wealth LLC boosted its stake in AbbVie by 1.7% during the 1st quarter. HORAN Wealth LLC now owns 25,081 shares of the company's stock valued at $5,505,000 after purchasing an additional 414 shares during the period. Baader Bank Aktiengesellschaft boosted its stake in AbbVie by 560.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 7,380 shares of the company's stock valued at $1,588,000 after purchasing an additional 6,263 shares during the period. Andra AP fonden boosted its stake in AbbVie by 44.2% during the 1st quarter. Andra AP fonden now owns 283,811 shares of the company's stock valued at $61,726,000 after purchasing an additional 86,969 shares during the period. Finally, Glenview Trust Co boosted its stake in AbbVie by 1.4% during the 1st quarter. Glenview Trust Co now owns 421,257 shares of the company's stock valued at $91,619,000 after purchasing an additional 5,930 shares during the period. Institutional investors own 70.23% of the company's stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie continued to draw bullish attention after reporting strong first-quarter results, with revenue and earnings coming in ahead of expectations and showing that growth is extending beyond Humira into newer drugs like Skyrizi and Rinvoq. AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.
• Positive Sentiment: AbbVie completed an early safety study for ABBV-142, which may improve investor confidence in the company’s pipeline and future oncology growth prospects. AbbVie Completes Early Safety Study for ABBV-142, Nudging Pipeline Hopes Higher
• Positive Sentiment: AbbVie and adMare BioInnovations named RIME Therapeutics as a Biotech Innovators Award winner, reinforcing AbbVie’s efforts to support early-stage biotech innovation and build optionality around its pipeline ecosystem. AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner
• Positive Sentiment: Skyrizi ranked ahead of J&J’s Tremfya in April drug ad spending, signaling continued competitive momentum and heavy marketing support for one of AbbVie’s key growth brands. AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
• Neutral Sentiment: Analyst commentary and Q1 earnings-call recaps highlighted ongoing interest in AbbVie’s post-Humira growth strategy, but these pieces were mostly interpretive rather than new market-moving disclosures. 5 must-read analyst questions from AbbVie’s Q1 earnings call
• Neutral Sentiment: Coverage on SKYRIZI expansion and reimbursement progress in Canada suggests continued international adoption, but the article framed these as part of an already constructive longer-term thesis rather than a single new catalyst. Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
• Negative Sentiment: One relative headwind is that ABBV shares have recently traded below key moving averages, reflecting some investor caution even as fundamentals remain solid.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.